Arcutis Biotherapeutics (ARQT) Cash from Investing Activities (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Cash from Investing Activities of -$11.3 million for Q1 2026, down 196.44% year-over-year from $11.7 million in Q1 2025, and up 66.85% quarter-over-quarter from -$34.2 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$11.3 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 196.44% year-over-year to -$11.3 million; the TTM figure through Mar 2026 stood at -$53.3 million (down 177.0% YoY), while the FY2025 annual figure was -$30.3 million, down 204.97% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$11.3 million, up from -$34.2 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $107.8 million in Q1 2023, with the low at -$197.3 million in Q3 2022.
- The 5-year median for Cash from Investing Activities is $15.3 million (2022), against an average of $4.7 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 5783.15% in 2022, then soared 604.39% in 2023.
- Arcutis Biotherapeutics' Cash from Investing Activities stood at $42.2 million in 2022, then sank by 247.36% to -$62.2 million in 2023, then jumped by 156.08% to $34.9 million in 2024, then plunged by 198.0% to -$34.2 million in 2025, then soared by 66.85% to -$11.3 million in 2026.
- Business Quant data shows ARQT's Cash from Investing Activities at -$11.3 million in Q1 2026, -$34.2 million in Q4 2025, and -$25.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | -15.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.22 Mn |
| Jun 30, 2026 | -15.22 Mn |
| Mar 31, 2026 | -11.33 Mn |
| Mar 31, 2026 | -11.33 Mn |
| Dec 31, 2025 | -34.18 Mn |
| Dec 31, 2025 | -34.18 Mn |
| Sep 30, 2025 | -25.25 Mn |
| Sep 30, 2025 | -25.25 Mn |
| Jun 30, 2025 | 17.42 Mn |
| Jun 30, 2025 | 17.42 Mn |
| Mar 31, 2025 | 11.75 Mn |
| Mar 31, 2025 | 11.75 Mn |
| Dec 31, 2024 | 34.88 Mn |
| Dec 31, 2024 | 34.88 Mn |
| Sep 30, 2024 | 84.78 Mn |
| Sep 30, 2024 | 84.78 Mn |
| Jun 30, 2024 | -62.14 Mn |
| Jun 30, 2024 | -62.14 Mn |
| Mar 31, 2024 | -28.70 Mn |
| Mar 31, 2024 | -28.70 Mn |